Clinical Trial Update: Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study (NET RETREAT) evaluating retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy versus the u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2 | Phase 2 | Status: RECRUITING